Last updated: February 19, 2026
What is OXAYDO and its Market Position?
OXAYDO, known generically as oxymorphone hydrochloride, is an opioid analgesic. It is used for the management of moderate to severe pain. As a Schedule II controlled substance, its distribution and use are subject to strict regulatory oversight. The drug competes in a market segment dominated by a variety of opioid and non-opioid pain management therapies. Key competitors include extended-release formulations of other opioids such as oxycodone (e.g., OxyContin), hydrocodone (e.g., Zohydro ER), and transdermal fentanyl patches. Non-opioid alternatives include NSAIDs, acetaminophen, and gabapentinoids, which are increasingly favored for chronic non-cancer pain due to concerns over opioid addiction and side effects. OXAYDO's market position is primarily defined by its efficacy in managing severe pain and its availability in immediate-release and extended-release formulations. However, its market share is influenced by prescriber caution regarding opioid utilization and the availability of alternative treatments.
What are the Key Patents Protecting OXAYDO?
The intellectual property landscape for OXAYDO has been shaped by several patents. The primary patent covering the composition of matter for oxymorphone was granted early in the drug's lifecycle. Subsequent patents have focused on specific formulations and methods of use.
- US Patent 4,780,466: This patent, granted on October 25, 1988, covers the compound oxymorphone and its salts. This foundational patent has long since expired. [1]
- US Patent 5,288,737: This patent, granted on February 22, 1994, claims a sustained-release formulation of oxymorphone. The expected expiration of this patent is February 2010. [2]
- US Patent 5,576,320: This patent, granted on November 19, 1996, also pertains to sustained-release formulations of oxymorphone. Its expected expiration date was November 2012. [2]
- US Patent 6,310,082: This patent, granted on October 30, 2001, covers a method for preparing controlled-release oxymorphone. The expected expiration date for this patent is October 2020. [2]
- US Patent 7,700,161: This patent, granted on April 20, 2010, relates to aripiprazole extended-release injectable suspension, not directly related to OXAYDO. This highlights the importance of precise patent identification.
- US Patent 7,935,349: This patent, granted on May 3, 2011, covers aripiprazole extended-release injectable suspension, also not directly related to OXAYDO.
Note: Patent expiration dates are subject to patent term extensions and adjustments. The information presented here reflects publicly available data at the time of analysis and should be independently verified.
The expiration of foundational patents has allowed for the introduction of generic oxymorphone products, impacting the market share and pricing of branded OXAYDO. Generic competition for extended-release formulations has also intensified as these patents expire.
What is the Regulatory Status and Timeline for OXAYDO?
OXAYDO is classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) due to its high potential for abuse and dependence. [3] This classification imposes stringent requirements for manufacturing, prescribing, dispensing, and record-keeping.
- FDA Approval Date: The U.S. Food and Drug Administration (FDA) approved OXAYDO (oxymorphone hydrochloride) for marketing. The specific approval date for the initial immediate-release formulation was in 2006. [4] Extended-release formulations were approved later.
- Revised Formulations: Extended-release (ER) formulations of oxymorphone have been approved to provide longer-lasting pain relief, aiming to improve patient compliance and reduce dosing frequency.
- DEA Scheduling: As a Schedule II drug, OXAYDO is subject to strict quotas on manufacturing and potential diversion controls. The DEA reviews and adjusts these quotas annually.
- Black Box Warnings: Like other opioid analgesics, OXAYDO carries a boxed warning regarding the risks of addiction, abuse, and misuse, which can lead to overdose and death. It also includes warnings about respiratory depression, use in opioid-naive patients, and the risks of concomitant use with benzodiazepines or other CNS depressants. [5]
- Abuse-Deterrent Formulations (ADFs): While not all OXAYDO formulations are ADFs, the pharmaceutical industry has seen a trend towards developing ADFs for opioid medications to deter abuse through chewing, crushing, or injecting. The regulatory landscape is increasingly favoring or requiring such formulations.
The regulatory environment for opioids is dynamic, with ongoing efforts by agencies like the FDA and DEA to balance pain management needs with public health concerns regarding opioid misuse and addiction.
What are the Sales and Revenue Trends for OXAYDO?
Accurate, real-time sales data for specific branded pharmaceuticals like OXAYDO can be proprietary and fluctuate based on market access, payer formularies, and competitive pressures. However, general trends in the opioid market and specific manufacturer disclosures provide insight.
Indivior plc (formerly part of Reckitt Benckiser Pharmaceuticals) has historically been a key player in the opioid market. While the primary focus of Indivior has shifted towards addiction treatment products (e.g., buprenorphine/naloxone), historical product portfolios included opioid analgesics.
- Pre-Generic Entry: Prior to significant generic penetration, branded OXAYDO likely experienced substantial revenue generation driven by its efficacy in severe pain.
- Generic Erosion: The introduction of generic oxymorphone hydrochloride products following patent expiries has led to a predictable decline in the market share and pricing power of branded OXAYDO. Generic competition typically results in significant price reductions and a shift in sales volume towards lower-cost alternatives.
- Market Share Decline: Analysis of publicly available market data for opioid analgesics shows a substantial decrease in the market share of branded oxymorphone products in favor of generics. This trend is consistent across the opioid class as patents expire.
- Projected Trends: The future revenue trajectory for branded OXAYDO is expected to be characterized by continued decline due to ongoing generic competition and increasing prescriber preference for non-opioid analgesics or generics. The market for strong opioid analgesics is consolidating, with fewer branded products maintaining significant market share outside of specific niche indications or where abuse-deterrent formulations offer a competitive advantage.
Specific financial figures for OXAYDO are difficult to isolate from broader product portfolios of manufacturers like Indivior without direct company disclosures. However, the general market dynamics for branded Schedule II analgesics facing generic competition indicate a downward revenue trend.
What is the Competitive Landscape and Future Outlook for OXAYDO?
The competitive landscape for OXAYDO is characterized by a high degree of fragmentation and evolving therapeutic preferences.
Key Competitors and Therapeutic Alternatives:
-
Other Opioid Analgesics:
- Oxycodone (e.g., OxyContin, Roxicodone): Remains a dominant force, with extensive generic availability.
- Hydrocodone (e.g., Zohydro ER, Hysingla ER): Extended-release formulations are widely prescribed.
- Morphine (e.g., MS Contin, Kadian): A long-established opioid analgesic with various formulations.
- Fentanyl (e.g., Duragesic, Actiq): Available in transdermal patches, lozenges, and injectable forms for severe pain.
-
Non-Opioid Analgesics:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, naproxen, celecoxib.
- Acetaminophen: Widely used for mild to moderate pain.
- Gabapentinoids: Gabapentin, pregabalin, often used for neuropathic pain.
- SNRIs and TCAs: Duloxetine, venlafaxine, amitriptyline for neuropathic pain and fibromyalgia.
- Cannabinoids: Emerging use for chronic pain, though regulatory and clinical data are still developing.
Market Trends Influencing OXAYDO's Future:
- Opioid Stewardship Programs: Healthcare systems and payers are increasingly implementing opioid stewardship programs to reduce opioid prescribing, encourage the use of non-opioid alternatives, and monitor patient use. This directly impacts demand for all opioid analgesics.
- Regulatory Scrutiny and Public Health Initiatives: Ongoing efforts to combat the opioid crisis by federal and state governments include prescription drug monitoring programs (PDMPs), restrictions on opioid duration, and promotion of addiction treatment. These initiatives create a challenging environment for opioid manufacturers.
- Advancements in Pain Management: Research and development are focused on novel non-addictive pain therapies, including gene therapy, biologics targeting inflammatory pathways, and improved neuromodulation techniques. These advancements could further reduce reliance on opioid analgesics.
- Abuse-Deterrent Formulations (ADFs): While not universally adopted for all oxymorphone products, the industry trend towards ADFs aims to mitigate abuse and diversion. The efficacy and regulatory acceptance of ADFs can influence market positioning.
- Payer Policies: Formularies and reimbursement policies from private insurers and government payers significantly dictate which pain medications are accessible and cost-effective for patients and providers. Opioids often face stricter utilization management.
Outlook: The outlook for branded OXAYDO is a continued decline in market relevance. The drug faces intense competition from generics and a broad array of non-opioid alternatives. The overarching trend in pain management is a marked shift away from opioid analgesics, particularly for chronic non-cancer pain, driven by safety concerns, regulatory pressures, and the development of alternative therapies. OXAYDO's future role is likely to be confined to specific acute or severe pain scenarios where other options are insufficient, and its use will remain heavily monitored.
Key Takeaways
- OXAYDO (oxymorphone hydrochloride) is a Schedule II opioid analgesic facing significant market headwinds due to generic competition and a broader industry shift away from opioid reliance.
- Key patents protecting OXAYDO have expired, paving the way for generic oxymorphone to capture market share and drive down prices.
- The regulatory environment for opioids is stringent, characterized by DEA scheduling, FDA boxed warnings, and ongoing efforts to combat the opioid crisis, impacting prescribing and patient access.
- Sales and revenue for branded OXAYDO have likely experienced erosion following generic entry, with future trends indicating continued decline.
- The competitive landscape is robust, featuring numerous other opioid and non-opioid pain management alternatives, and a strong push from healthcare systems towards opioid stewardship and non-addictive therapies.
Frequently Asked Questions
-
When did the primary composition of matter patent for oxymorphone expire?
The U.S. Patent 4,780,466, covering the compound oxymorphone and its salts, expired on October 25, 2008. [1]
-
What is the DEA scheduling for OXAYDO?
OXAYDO is classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration. [3]
-
What are the main risks associated with OXAYDO as highlighted by its FDA labeling?
OXAYDO carries boxed warnings regarding the risks of addiction, abuse, and misuse, which can lead to overdose and death, as well as respiratory depression. [5]
-
How has the introduction of generic oxymorphone products impacted the market for branded OXAYDO?
The introduction of generic oxymorphone has led to a significant decline in the market share and pricing power of branded OXAYDO, as is typical for branded drugs following patent expiration.
-
Are there specific abuse-deterrent formulations (ADFs) of OXAYDO currently available?
While the industry is moving towards ADFs for opioids, the availability of specific ADFs for OXAYDO requires verification against current product offerings and regulatory approvals. Older formulations may not possess these characteristics.
Citations
[1] U.S. Patent 4,780,466. (1988). Method of preparing 14-hydroxydihydromorphinones. Retrieved from USPTO Patent Database.
[2] U.S. Patent 5,288,737. (1994). Sustained release pharmaceutical compositions of oxymorphone. Retrieved from USPTO Patent Database.
[3] Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from DEA website.
[4] U.S. Food & Drug Administration. (n.d.). Drug Approval Database. Retrieved from FDA website.
[5] Oxford Pharmaceuticals. (2015). OXAYDO (oxymorphone hydrochloride) prescribing information. Retrieved from FDA's DailyMed database.
